Zhongxi Biotech Completes Nearly 100 Million Yuan Series A Financing to Accelerate Smart Lab Deployment and Global Expansion

Since its establishment in 2014, Zhongxi Biology has been deeply engaged in the field of life science laboratory automation, focusing on the research, development, and production of laboratory automation systems and consumables. Grounded in independent innovation of core underlying technologies and supported by intelligent manufacturing collaboration across the entire industrial chain, the company steadfastly fulfills its mission as "a promoter of life science automation." Zhongxi Biology has successfully achieved a leapfrog development from key technological breakthroughs to the construction of a complete ecosystem, with research and production bases established in Suzhou, Nanjing, Xiangyang, and Guangzhou.

Extensive coverage of products and ecosystem:Zhongxi Biology has established an automated solution system covering dozens of cutting-edge fields including genomics, cell biology, drug discovery, protein science, analytical chemistry, and synthetic biology, implementing over a hundred laboratory scenario application solutions.

Customer and market recognition and trust:Zhongxi Biotech's services cover more than 10 countries and regions worldwide, including the United States, Japan, Germany, and South Korea. The company has accumulated over 6,000 installed devices globally, serving more than 3,000 customers, including medical institutions, research organizations, pharmaceutical and biotechnology enterprises, as well as industrial and government agencies.

Facing the significant challenges brought by the massive growth of experimental data, increasingly complex experimental procedures, and ever-higher quality requirements in life science research to traditional laboratory models, Zhongxi Bio has innovatively launched an intelligent laboratory management system centered on "full-scenario, full-chain, and full-ecosystem." Relying on Zhongxi Bio's self-developed intelligent hardware matrix, the system establishes a fully digital closed loop from sample processing to data analysis, providing a one-stop digital solution. It can significantly enhance laboratory management efficiency, experimental traceability, and overall research capabilities, and is expected to help more laboratories achieve digital transformation and promote the advancement of industry-wide management standards.

To support its globalization strategy and market expansion, Zhongxi Biology has simultaneously built a full-chain global supply network covering "R&D - manufacturing - services." By deploying an advanced digital supply chain management system, the company has achieved efficient cross-border resource collaboration and optimized allocation.

Meanwhile, by leveraging localized technical adaptation capabilities and a rapid-response service mechanism, Zhongxi Biology is accelerating the global market penetration of its intelligent laboratory solutions, continuously increasing its international market share and brand influence.

Zhongxi Bio's founder Zhu BinStated: "Laboratory automation in life sciences is a core enabler for efficiency improvement and intelligent transformation. This round of financing will drive the company’s strategic upgrade from a supplier of equipment and consumables to a full-process ecosystem service provider, leveraging its fundamental R&D and manufacturing advantages to continuously deliver high-value intelligent solutions, supporting the intelligent transformation of global research and industrial customers."

Project Leader of China Capital Management Co., Ltd."With the advancement of AI and life science technologies, experimental throughput, data quality, and data traceability are becoming increasingly important, and laboratory automation is expected to address the limitations of traditional manual operations. Leveraging its cross-disciplinary R&D capabilities and advantages in large-scale manufacturing, Zhongxi Biology is poised to accelerate the adoption of laboratory automation through an ecosystem-based product portfolio."

Dr. Chen Kan, Partner at Qiming Venture Partners and Co-Head of the Healthcare Sector"Zhongxi Biology leverages its team's strengths in both technological R&D and commercialization, driving the intelligent development of life sciences through an open ecosystem strategy with laboratory automation as the core focus. We look forward to Zhongxi Biology leading efficiency transformation and industrial upgrading in the life sciences field through standardized solutions."

China Capital Management Co., Ltd. was registered and established in Beijing on July 31, 2009, as a wholly-owned subsidiary of China Securities Co., Ltd., with registered capital of RMB 3.5 billion, specializing in private equity investment fund management. The funds managed by China Capital Management cover direct equity investment funds, market-oriented fund-of-funds, and infrastructure investment funds, primarily targeting high-growth enterprises and companies with merger and acquisition value in industrial consolidation, across sectors including technology and telecommunications, healthcare and pharmaceuticals, clean energy, new materials, advanced manufacturing, defense, energy conservation and environmental protection, culture-tourism consumption, and infrastructure. China Capital Management currently oversees more than 80 registered funds, with total assets under management exceeding RMB 100 billion.

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages 11 U.S. dollar funds and 7 RMB funds, with total assets under management reaching 9.5 billion U.S. dollars. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in the technology and consumer (T&C), healthcare sectors.

To date, Qiming Venture Partners has invested in more than 580 rapidly growing innovative companies, over 210 of which have gone public on exchanges such as the NYSE, NASDAQ, Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have exited through mergers and acquisitions. More than 80 of these companies have become industry-recognized unicorns or super unicorns.

Related reading:Bringing liquid handling workstations down to the "10,000-yuan range" and serving nearly 3,000 customers, Zhongxi Biology aims to popularize life science automation